Why Intercept Might Be A Better Bet Than Biogen Right Now

Loading...
Loading...

Christian Tharp was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.

Biotech Expert and "Five-Star Stock Watch" Author Christian Tharp commented on biotech stocks last Friday.

Tharp noted that Intercept Pharmaceuticals Inc ICPT had spiked higher and that he liked it if it could stay above the $300 level.

Shares of Biogen Idec Inc BIIB had already shot up Friday morning and Tharp was more cautious on the stock as compared to Intercept Pharmaceuticals.

Tharp cautioned that biotech as a group had kept moving higher and that traders "don't want to miss the party," however, Tharp compared the surge to the housing market and felt that "when it ends, it doesn't end well."

On Monday, Intercept Pharmaceuticals closed at $269.82, down 7.27 percent.

Biogen also closed down at $463.73, a decline of 2.57 percent.

Listen to the show here

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechExclusivesTrading IdeasGeneralChristian Tharp
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...